ADMA Biologics (ADMA) stock has been in focus after short seller Culper Research alleged channel stuffing related to ASCENIV, prompting multiple securities law firms to launch investigations and potential class action lawsuits.

At a share price of $8.41, ADMA’s recent trading reflects sharp swings, with a 1-day share price gain of 6.73% sitting against a 7-day decline of 17.95% and a 90-day fall of 48.34%. The 5-year total shareholder return remains very large, suggesting long term holders have still seen meaningful gains despite current pressure from legal headlines, competitive IVIG pricing, and trimmed guidance.

If this mix of legal risk and long term gains has you rethinking your exposure to healthcare, it could be a useful moment to scan for other potential opportunities in 33 healthcare AI stocks

With earnings per share at $0.19, legal questions hanging over ASCENIV and the stock trading well below some analyst targets, investors now face a key question: is there a buying opportunity here, or is future growth already priced in?

Most Popular Narrative: 59.8% Undervalued

According to the most followed narrative, ADMA Biologics' fair value of $20.93 sits well above the last close at $8.41, pointing to a large valuation gap that some investors are watching closely.

Reverse discounted cashflow at current TTM revenue of 383 MUSD at 35% FCF, 134 MUSD, revenue needs to grow 16%/y over next 10 years to justify current price (if ADMA gets to 1 BUSD of revenue by 2029, growth of 21%/year), currently undervalued.

This narrative leans heavily on rising revenue, wider margins and a future earnings multiple that assumes the business matures into a much larger, more profitable plasma specialist. It highlights the importance of the specific growth and profitability assumptions underlying the $20.93 fair value and how sensitive the estimate may be to relatively small changes in those inputs.

Result: Fair Value of $20.93 (UNDERVALUED)

However, this hinges on management delivering on growth and margin assumptions while legal investigations into ASCENIV, and any impact on demand or pricing, remain unresolved catalysts.

Next Steps

If the mix of opportunity and concern in this story leaves you undecided, quickly review the key data and weigh it against your own risk tolerance, including the balance of 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If ADMA’s situation feels finely balanced, do not stop here. Keep building a watchlist of fresh ideas that fit your style before the next move passes you by.

• Target potential mispricings by scanning a focused group of 45 high quality undervalued stocks that combine compelling fundamentals with room for the market to reassess expectations.
• Prioritise resilience by reviewing solid balance sheet and fundamentals stocks screener (46 results) that may better withstand business shocks and funding pressures over the long haul.
• Get ahead of the crowd by filtering through a screener containing 22 high quality undiscovered gems that the broader market might not be paying close attention to yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.